Clinical Trial

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05334823
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Enrollment 100 participants
Start Date 2022-01-26
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-31